Sunday, March 23, 2025 4:54:59 PM
it seems this stock canf is being manipulated.when there is news the stock jumps and the next
day it drops . no point to put out news . the stock is being manipulated. or the news is unreliable
basically there is one person always messaging . i wonder if he has interest in the company . or he is
flipping the stock to make money.
day it drops . no point to put out news . the stock is being manipulated. or the news is unreliable
basically there is one person always messaging . i wonder if he has interest in the company . or he is
flipping the stock to make money.
Recent CANF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 12:34:19 PM
- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months • GlobeNewswire Inc. • 04/30/2026 12:31:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 08:15:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 11:59:42 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/06/2026 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/03/2026 09:07:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:22:12 AM
- Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 • GlobeNewswire Inc. • 03/30/2026 11:20:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/26/2026 02:05:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 01:29:33 PM
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient • GlobeNewswire Inc. • 03/26/2026 01:27:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/17/2026 11:50:36 AM
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance • GlobeNewswire Inc. • 03/17/2026 11:47:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 08:30:01 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/05/2026 12:31:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:29:04 PM
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds • GlobeNewswire Inc. • 03/04/2026 03:25:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 12:05:05 PM
- Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/17/2026 12:01:59 PM
- Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/09/2026 12:12:14 PM
